Our Team

The award-winning Engimata team has experience in all stages of drug development. 

Mitra Mosharraf, PhD Pharm Sci, MBA

Chief Executive Officer

Dr. Mosharraf has over 20 years of experience in all stages of drug development and life cycle management of biotechnology drug products from companies such as Pfizer (Principal Scientist), HTD Biosystems (CSO) and Santen (Director, Product Development, Biologics). She received her MSc (Pharmacy) and PhD (Pharm Sci) from Uppsala University (Sweden) and executive MBA from Massachusetts Institute of Technology. She is an inventor on 4 patents, and author of 14 peer reviewed papers and 50 conference proceedings on importance of solid-state structure and molecular interactions for stability and efficacy of pharmaceutical drug products.

Rajiv Nayar, PhD Biochemistry

Chief Scientific Officer

Dr. Nayar has over 35 years of experience in biotechnology drug development from Bayer (Head of Protein Formulation Development), Canadian Liposome Company and HTD Biosystems (Founder & President) where he led development of a botulinum vaccine and several liposomal vaccines. He holds a PhD in Biochemistry from the University of British Columbia and was a Medical Research Council Fellow at M.D Anderson Tumor Institute. He is an inventor on 26 patents and author of 70 publications on liposomal drug delivery, proteins, and vaccines. He has been involved in the development of a pentavalent botulinum vaccine, liposomal vaccines, DNA vaccines, and a QS-21 based Alzheimer's vaccine

Aryo Sorayya, BSc, MD’ 22

Chief Medical Officer

Aryo graduated from Stanford University and is currently a 3rd year medical student at Virginia Tech Carilion School of Medicine. Aryo has conducted research at institutions such as NASA Ames (as a member of the Stanford iGEM team), at the Stanford VA hospital, at the Stanford School of Medicine (Wu and Attardi labs), and at Virginia Tech Carilion School of Medicine. He is co-inventor of Engimata’s adjuvant technology and has won more than 20 scientific awards for his vaccine research and placed as a finalist at Stanford business competitions. He is author of 3 publications and inventor of two patents.